Skip to main content
OpenTrials
Completed

NCT Number: NCT07709936

Oculomotor Rehabilitation After Concussion in Adults: A Feasibility Study

After concussion, many individuals experience vision-related symptoms such as blurred vision, difficulty reading, and discomfort in visually stimulating environments, which can interfere with return to work, school, and daily activities. Oculomotor rehabilitation (OMR) is used by some clinicians to address these symptoms, but there is limited high-quality evidence to support its use. Prior to conducting a fully powered randomized controlled trial, it is necessary to determine whether such a study is feasible. This study aims to evaluate the feasibility of conducting a randomized trial comparing a six-week OMR program to usual care in adults with concussion. Adults aged 18 to 42 years who sustained a concussion 30 days to 12 months prior and report symptoms suggestive of oculomotor impairment will be recruited from an outpatient concussion clinic at the University Health Network and the community in Toronto, Ontario. Participants will be randomized to either a six-week OMR program consisting of weekly 60-minute clinic visits using head-mounted eye-tracking technology with prescribed home exercises, or usual care consisting of education and symptom management strategies. Feasibility outcomes will include recruitment rate, retention, perceived benefit of the OMR intervention, and safety (adverse events). Outcomes will be assessed at baseline and after six weeks. The findings will inform the design and implementation of a future trial evaluating the effectiveness of oculomotor rehabilitation after concussion.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–42 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

KITE University Health Network

Toronto, Ontario, M5G 2A2, Canada

About this study

Background Concussion is a common form of mild traumatic brain injury (mTBI) that produces a broad and heterogeneous range of symptoms and functional deficits affecting daily activities including work, school, sport, and social participation. Recovery is highly individualized and influenced by injury characteristics, personal medical history (e.g., anxiety, migraine history), and biological sex and sociocultural gender. Over 50% of individuals from the general population experience symptoms beyond four weeks. In mixed-mechanism populations, mean time to recovery is approximately 6.5 weeks for females and 5.5 weeks for males, suggesting that females may experience a longer symptom course following concussion.

Among the most prevalent clinical profiles of concussion are symptoms attributable to oculomotor dysfunction. Functional deficits in saccades, smooth pursuits, vergence, and pupillary light reflex occur far more frequently than structural injuries, making them a feasible and clinically important rehabilitation target. These deficits can manifest as blurred vision, dizziness, light sensitivity, eye strain, and difficulty tolerating visually busy environments, with downstream impacts on return to work, school, and sport. Without directed rehabilitation, these symptoms often persist.

Oculomotor rehabilitation (OMR) aims to retrain impaired eye movement functions through targeted, restitutive exercise protocols. A systematic review conducted by the study team demonstrated improvements in near point of convergence, reading rate, and visual search and attention following OMR; however, certainty of evidence was rated as low due to methodological limitations, small sample sizes, and variability in protocols. Since that review, additional studies have been published strengthening the evidence base, though existing randomized controlled trials have focused predominantly on adolescents and young adults, limiting generalizability to older adult populations.

Interest in virtual reality (VR)-based OMR delivery has grown substantially. A recent scoping review identified 10 studies using VR for post-concussion vestibular rehabilitation, reporting good tolerability and greater participant enjoyment relative to traditional approaches. To the investigators' knowledge, no published study has systematically examined the feasibility, acceptability, or perceived benefit of delivering OMR via head-mounted VR goggles combined with mobile application-based home exercise programming in adults with persisting oculomotor deficits post-concussion.

Biological sex and sociocultural gender differences in concussion reporting, symptom experience, and recovery have been documented, yet sex and gender have not been adequately explored in the context of OMR. This trial is designed to collect sex-disaggregated data to inform future research in this area.

Objectives The primary objective is to assess the feasibility of a future fully powered RCT, operationalized across four a priori criteria: recruitment, retention, adherence, and technology reliability.

The secondary objective is proof-of-concept, operationalized a priori as participant-rated perceived benefit (0-4 scale) at study completion.

Study Design This is a feasibility RCT with two parallel intervention groups, a 1:1 allocation ratio, conducted at Toronto Rehabilitation Institute (TRI)-University Health Network (UHN), Ontario, Canada.

Recruitment Participants are recruited through hospital- and community-based concussion clinics, community-based brain injury organizations, and social media platforms. Individuals who participated in prior research at the Hull-Ellis Concussion and Research Clinic, had not recovered, and had indicated willingness to be contacted for future eligible studies are also approached. Interested individuals undergo telephone-based screening followed by in-person confirmation of visually based eligibility criteria. Written informed consent is obtained prior to enrolment.

Eligibility

  • Adults (18 to 42 years of age) with a diagnosis of a concussion by a medical doctor between 30 days and 12 months prior
  • Endorsed oculomotor related symptoms indicated by rating "moderate" or "severe" blurred-vision, double vision and/or light sensitivity.
  • Normal stereopsis (depth perception) as measured with the Stereo Fly Test
  • Equal (within one line difference) visual acuity between eyes as measured with the Snellen Eye Chart (Snellen, 1892) (corrected, as applicable)
  • Intact extraocular movements and visual fields
  • Pupils equal, round, and reactive to light and accommodation
  • Healthy fundoscopic findings
  • Ability to read and communicate in English

Exclusion criteria

  • Diagnosed eye disease (i.e. gloucoma)
  • Visual acuity less than 20/80
  • Severe neurocognitive deficits expected to interfere with participation
  • Residence more than 100 km from the study site.

Baseline Measures Baseline data include demographics, medical history, injury characteristics, and the following validated questionnaires: Brain Injury Visual Symptom Survey (BIVSS), Convergence Insufficiency Symptoms Survey (CISS), RPQ, Patient Health Questionnaire-9 (PHQ-9), Fatigue Severity Scale (FSS), Insomnia Severity Index (ISI), Sheehan Disability Scale (SDS), Traditional Masculinity and Femininity Scales (TMS/TFS), and the Visually Induced Motion Sickness Susceptibility Questionnaire (VIMSSQ). Clinical assessments include near point of convergence break (NPC, in centimeters) and critical flicker fusion (CFF, in hertz).

Interventions Oculomotor Rehabilitation (OMR) Group: Participants receive six weekly in-person sessions of progressive, personalized OMR delivered via head-mounted VR goggles (FOVE) using NeuroFlex software, targeting saccades, smooth pursuits, vergence, gaze stability, optokinetic reflex, and anti-saccades. Sessions increase progressively in difficulty and duration based on individual tolerance. Between sessions, participants complete daily home-based eye movement exercises via a study-specific mobile application, targeting at least 10 minutes per day, five days per week.

Usual Care (UC) Group: Participants receive education on visual symptom-limiting strategies (e.g., pacing, screen modification). No active or sham intervention is provided.

Randomization and Allocation Participants are randomized 1:1 to OMR or UC following consent, using a blinded, sex-stratified randomization schema with variable block sizes generated a priori. Blinding of participants and study personnel after allocation is not possible given the nature of the intervention.

Outcome Measures Primary Feasibility Outcomes are assessed against a priori traffic light criteria (Green/Amber/Red) and include: recruitment rate, randomization rate, compliance to allocated arm, and retention rate.

Additional Feasibility Outcomes include: magnitude of co-intervention, VR tolerability, homework participation, study experience rating (0-4), technology reliability, and the ability of the technology to capture change in oculomotor metrics between baseline and final assessment.

Secondary Outcome: Participant-rated perceived benefit (0-4) at study completion.

Data Analysis Descriptive statistics are used to summarize feasibility outcomes and participant characteristics. The study is not powered for efficacy testing and between-group comparisons are not emphasized. Variability estimates will inform power calculations for a future full-scale RCT. Data are captured in REDCap and analyzed in SPSS (Version 25). A missing data threshold of 5% is set a priori, with complete case analysis below this threshold and multiple imputation applied above it.

Findings from this feasibility trial will be used to inform the design of a future fully powered pragmatic RCT. Feasibility metrics including recruitment and retention rates, compliance to allocated arm, and technology reliability, will be evaluated against a priori traffic light criteria to determine whether, and under what conditions, progression to a full trial is warranted. Variability estimates across candidate clinical outcomes and review of recent published literature will additionally inform outcome selection and power analysis planning for the future trial.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults (18 to 42 years of age) with a diagnosis of a concussion by a medical doctor between 30 days and 12 months prior
  • Endorsed oculomotor related symptoms indicated by rating "moderate" or "severe" blurred-vision, double vision and/or light sensitivity.
  • Normal stereopsis (depth perception) as measured with the Stereo Fly Test
  • Equal (within one line difference) visual acuity between eyes as measured with the Snellen Eye Chart (Snellen, 1892) (corrected, as applicable)
  • Intact extraocular movements and visual fields
  • Pupils equal, round, and reactive to light and accommodation
  • Healthy fundoscopic findings
  • Ability to read and communicate in English

Exclusion criteria

  • Diagnosed eye disease (i.e. glaucoma)
  • Visual acuity less than 20/80 measured using the Snellen Eye Chart
  • Severe neurocognitive deficits expected to interfere with participation
  • Residence more than 100 km from the study site

Treatment and study plan

Usual Care

Other

The UC group is education only and consists of education on visual symptom-limiting strategies and resources. These include strategies such as pacing and taking breaks during visual work, strategies to modify a visual stimulus such as increasing font size on a mobile application or changing to dark mode. An active or 'sham' is not provided.

Oculomotor exercises delivered in virtual reality

Other

Participants engage in eye movement training based on the following movements:

  • Saccade: The ability of the eyes to shift the center of gaze quickly and accurately between targets, for example in reading
  • Anti-saccade: An eye movement that is made in the opposite direction of a visual stimulus
  • Smooth pursuit: A slow tracking eye movement, designed to keep a moving stimulus on the retina
  • Pursuit head free: A complex, coordinated movement where both the eyes and the head move to follow a single, slow-moving object
  • Optokinetic reflex: Involuntary eye movements that are triggered when watching an object moving through a visual field. It combines smooth pursuit in one direction, and a quick saccade back
  • Vergence: Disjunctive movements of the eyes (convergence or divergence) that align the fovea of each eye with targets located at different distances from the observer.

Between study visits, participants compete home based exercises on a smart phone or tablet.

Primary outcomes

  1. Feasibility of Recruitment

    Time frame: 12 months

    Defined as the ability to recruit at least 32 individuals over a 12 month period.

  2. Perceived Benefit of the Intervention by Participants Allocated to OMR.

    Time frame: Measured at final testing (8 weeks post enrollement).

    Perceived benefit of OMR in contributing to improvement in symptoms of concussion of at least 85% as measured on a scale of 0-4 (0 no benefit to 4 significant benefit) as reported after participating in 6 weekly sessions of OMR. Measured at final testing for participants in the OMR group.

  3. Completion Rate of at Least 85%

    Time frame: At study completion (approximately 8 weeks per participant).

    The percentage of participants completing all study requirements including: Baseline data collection, the assigned intervention, and final testing. The assigned intervention as described in the intervention section.

  4. Harms or Adverse Events

    Time frame: From enrolment to final testing at 8 weeks post enrolment.

    No harms or adverse events (undesirable or unintended medical occurrence experienced by a study participant, regardless of whether it is directly caused by the intervention) reported by any participant from baseline through final testing, including during and immediately after intervention.

Secondary outcomes

  1. Randomization Rate

    Time frame: Over the 12-month recruitment period.

    The proportion of eligible participants who enrolled and were randomized out of the total number of individuals interested in the study.

  2. Compliance to Allocated Treatment Arm

    Time frame: Over 6 week intervention period, measured at final testing 8 weeks post enrollment.

    The proportion of participants who adhered to their assigned arm allocation (no withdrawals or crossovers) through study completion.

  3. Magnitude of Co-intervention

    Time frame: Throughout the 6-week intervention period.

    Frequency and nature of non-study rehabilitation or therapeutic interventions participants engaged in during the study period, as self-reported.

  4. Tolerance to VR-based Assessment and Training

    Time frame: Immediately after each weekly OMR intervention session; (for 6 weeks).

    Measured using the Simulator Sickness Questionnaire (SSQ; Kennedy et al., 1993), a 16-item scale (0=not at all, 3=severe) oculomotor and nausea related symptoms.

  5. Homework Participation

    Time frame: Measured weekly over the 6-week intervention period.

    Number of days participants reported completing at-home eye movement exercises (out of 5 days per week, excluding weekends).

  6. Study Experience Rating

    Time frame: Measured once after final testing (8 weeks post enrollment).

    Overall perceived experience with the study rated on a 0-4 scale (0=negative, 2=neutral, 4=positive)

  7. Technology Reliability

    Time frame: At each participant visit over the entire study period (approximately 16 months).

    Frequency of technology failures during VR delivery requiring rescheduling or session interruption.

  8. Oculomotor Metrics Capture

    Time frame: From baseline to final testing 8 weeks post enrollment.

    The ability of the VR platform to capture clinically meaningful change in oculomotor parameters (saccade latency, smooth pursuit gain, vergence amplitude) between baseline and final testing.

  9. BIVSS Feasibility as Primary Outcome

    Time frame: Baseline and final testing (8 weeks post-randomization)

    Participant completion rates and variance estimates of the Brain Injury Visual Symptom Survey (BIVSS, score range 0-112; higher=worse symptomology) to inform power calculations for a future trial.

Sponsors and collaborators

Lead sponsor

University Health Network, Toronto

Other

Collaborators

  • Mitacs
  • University of Toronto

Registry information

Acronym: ORCA

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jul 17, 2026
Registry last updated
Jul 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.